JP2013520428A - ジアシルグリセロールリパーゼの阻害剤として使用するためのグリシンクロマン−６−スルホンアミド - Google Patents

ジアシルグリセロールリパーゼの阻害剤として使用するためのグリシンクロマン−６−スルホンアミド Download PDF

Info

Publication number
JP2013520428A
JP2013520428A JP2012553986A JP2012553986A JP2013520428A JP 2013520428 A JP2013520428 A JP 2013520428A JP 2012553986 A JP2012553986 A JP 2012553986A JP 2012553986 A JP2012553986 A JP 2012553986A JP 2013520428 A JP2013520428 A JP 2013520428A
Authority
JP
Japan
Prior art keywords
sulfonamido
acetic acid
methyl
dimethylchroman
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012553986A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013520428A5 (cg-RX-API-DMAC10.html
Inventor
シュアンフア・フ
ヤジョン・フアン
ミン・ディン
ルイーズ・エス・チュパック
ジャン・シャオファン
ロバート・ジー・ジェントルズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2013520428A publication Critical patent/JP2013520428A/ja
Publication of JP2013520428A5 publication Critical patent/JP2013520428A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2012553986A 2010-02-19 2011-02-16 ジアシルグリセロールリパーゼの阻害剤として使用するためのグリシンクロマン−６−スルホンアミド Ceased JP2013520428A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30602310P 2010-02-19 2010-02-19
US61/306,023 2010-02-19
PCT/US2011/025041 WO2011103156A1 (en) 2010-02-19 2011-02-16 Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase

Publications (2)

Publication Number Publication Date
JP2013520428A true JP2013520428A (ja) 2013-06-06
JP2013520428A5 JP2013520428A5 (cg-RX-API-DMAC10.html) 2014-04-03

Family

ID=43743459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012553986A Ceased JP2013520428A (ja) 2010-02-19 2011-02-16 ジアシルグリセロールリパーゼの阻害剤として使用するためのグリシンクロマン−６−スルホンアミド

Country Status (5)

Country Link
US (1) US8354548B2 (cg-RX-API-DMAC10.html)
EP (1) EP2536704B1 (cg-RX-API-DMAC10.html)
JP (1) JP2013520428A (cg-RX-API-DMAC10.html)
CN (1) CN102858760A (cg-RX-API-DMAC10.html)
WO (1) WO2011103156A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3095787A1 (en) * 2015-05-22 2016-11-23 Universiteit Leiden Pharmaceutically active compounds as dag-lipase inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10507465A (ja) * 1994-11-14 1998-07-21 セフアロン・インコーポレーテツド 多機能プロテアーゼ阻害剤
JP2002533322A (ja) * 1998-12-22 2002-10-08 エフ．ホフマン−ラ ロシュ アーゲー ヒドロキサム酸スルホンアミド

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1160248A1 (en) * 2000-05-31 2001-12-05 Pfizer Inc. N-(Isoxazol-5-yl)-sulfonamide derivatives and their use as endothelin antagonists
JP4114859B2 (ja) * 2002-01-09 2008-07-09 松下電器産業株式会社 動きベクトル符号化方法および動きベクトル復号化方法
WO2006066756A1 (en) * 2004-12-21 2006-06-29 F. Hoffmann-La Roche Ag Chroman derivatives and uses thereof in the treatment of cns disorders
CN101300246A (zh) * 2005-11-03 2008-11-05 弗·哈夫曼-拉罗切有限公司 作为5－ht6抑制剂的芳基磺酰基色满类化合物作为蛋白激酶抑制剂的吲哚基马来酰亚胺衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10507465A (ja) * 1994-11-14 1998-07-21 セフアロン・インコーポレーテツド 多機能プロテアーゼ阻害剤
JP2002533322A (ja) * 1998-12-22 2002-10-08 エフ．ホフマン−ラ ロシュ アーゲー ヒドロキサム酸スルホンアミド

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6015007312; ＨＯＯＶＥＲ，　Ｈ．　Ｓ．　ｅｔ　ａｌ．: 'Ｓｅｌｅｃｔｉｖｉｔｙ　ｏｆ　ｉｎｈｉｂｉｔｏｒｓ　ｏｆ　ｅｎｄｏｃａｎｎａｂｉｎｏｉｄ　ｂｉｏｓｙｎｔｈｅｓｉｓ　ｅｖａｌｕａｔｅｄ　ｂｙ　ａｃｔｉｖｉｔｙ-ｂａｓｅｄ　ｐｒｏｔｅｉｎ　ｐｒｏｆｉｌ' ＢＩＯＯＲＧＡＮＩＣ　＆　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ　ＬＥＴＴＥＲＳ １８　（２）, 2008, ｐ．５８３８-５８４１ *
JPN6015007314; ＲＥＷＩＮＫＥＬ，　Ｊ．　Ｂ．　Ｍ．　ｅｔ　ａｌ．: '１-ＡＭＩＮＯＩＳＯＱＵＩＮＯＬＩＮＥ　ＡＳ　ＢＥＮＺＡＭＩＤＩＮＥ　ＩＳＯＳＴＥＲ　ＩＮ　ＴＨＥ　ＤＥＳＩＧＮ　ＡＮＤ　ＳＹＮＴＨＥＳＩＳ　ＯＦ　ＯＲＡＬＬＹ　ＡＣＴＩＶＥ　ＴＨＲＯＭＢＩＮ　ＩＮＨ' ＢＩＯＯＲＧＡＮＩＣ　＆　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ　ＬＥＴＴＥＲＳ ９　（５）, 1999, ｐ．６８５-６９０ *

Also Published As

Publication number Publication date
US20110207772A1 (en) 2011-08-25
EP2536704A1 (en) 2012-12-26
CN102858760A (zh) 2013-01-02
WO2011103156A1 (en) 2011-08-25
EP2536704B1 (en) 2014-01-15
US8354548B2 (en) 2013-01-15

Similar Documents

Publication Publication Date Title
AU2014290411B2 (en) Sulfonamides as modulators of sodium channels
EP2697213B1 (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses
RU2763936C1 (ru) Производные 1,3,4-оксадиазола, как ингибитор гистондезацетилазы 6 и содержащая их фармацевтическая композиция
WO2005012221A1 (ja) ジフェニルエーテル化合物、その製造方法および用途
JP2009536613A (ja) Ｃｂ２受容体を調節する化合物
JP2009515887A (ja) 神経系疾患のための治療薬としてのヒストンデアセチラーゼ阻害剤
JP6114316B2 (ja) カルシウム感知受容体調節剤としての置換クロマン化合物
EA024702B1 (ru) Новые иммуномодуляторные и противовоспалительные соединения
JP4571863B2 (ja) 抗痛覚過敏剤として有用なキナゾリノン誘導体
EP2139852A1 (en) Sulfonamide derivatives with therapeutic indications
CN101505751A (zh) 8-羟基喹啉化合物和其方法
CN111741948B (zh) 饱和环稠合的二氢嘧啶酮或二氢三嗪酮化合物及其药物用途
US6831080B2 (en) Cinnamide derivatives as KCNQ potassium channel modulators
HUP0105073A2 (hu) 2-Amino-piridin-származékok, ezek alkalmazása gyógyszerként és ezeket tartalmazó gyógyászati készítmények
US20250197420A1 (en) Macrocyclic compounds, compositions, and methods of using thereof
RS57071B1 (sr) Jedinjenja fluorofenil pirazola
WO2002102780A1 (en) Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient
CN105008345A (zh) 可用作gpr120的激动剂的双环吡咯衍生物
US8354548B2 (en) Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase
WO2013091285A1 (zh) 一种脲类化合物、制备方法及其用途
JP2013520423A (ja) ジアシルグリセロールリパーゼ阻害剤としての使用のためのグリシンスルホンアミド
RU2194046C2 (ru) Новые нитрометилкетоны, способ их получения и содержащие их композиции
EP1844775B1 (en) Therapeutic agent for the treatment of herpes progenitalis after development of lesions
TW201605769A (zh) 取代萘化合物作為鈣敏感受體調節劑
EP2464629A1 (en) Selective sphingosine-1-phosphate receptor antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140213

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150224

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20150630